WO2003040170A3 - Antibodies to cd40 - Google Patents

Antibodies to cd40 Download PDF

Info

Publication number
WO2003040170A3
WO2003040170A3 PCT/US2002/036107 US0236107W WO03040170A3 WO 2003040170 A3 WO2003040170 A3 WO 2003040170A3 US 0236107 W US0236107 W US 0236107W WO 03040170 A3 WO03040170 A3 WO 03040170A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
relates
human anti
nucleic acid
acid molecules
Prior art date
Application number
PCT/US2002/036107
Other languages
French (fr)
Other versions
WO2003040170A9 (en
WO2003040170A2 (en
Inventor
Vahe Bedian
Ronald P Gladue
Jose Corvalan
Xiao-Chi Jia
Xiao Feng
Original Assignee
Pfizer Prod Inc
Abgenix Inc
Vahe Bedian
Ronald P Gladue
Jose Corvalan
Xiao-Chi Jia
Xiao Feng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23370387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003040170(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MEP-2008-814A priority Critical patent/ME00503B/en
Priority to ES02802898T priority patent/ES2432968T3/en
Priority to EA200400654A priority patent/EA011449B1/en
Priority to AU2002356926A priority patent/AU2002356926B2/en
Priority to JP2003542215A priority patent/JP4616555B2/en
Priority to CA2466128A priority patent/CA2466128C/en
Priority to BRPI0214137A priority patent/BRPI0214137B8/en
Priority to DK02802898.3T priority patent/DK1476185T3/en
Priority to SI200231036T priority patent/SI1476185T1/en
Priority to EP02802898.3A priority patent/EP1476185B1/en
Priority to HU0402247A priority patent/HU229829B1/en
Priority to CN028245709A priority patent/CN1582165B/en
Priority to NZ533180A priority patent/NZ533180A/en
Priority to APAP/P/2004/003034A priority patent/AP1918A/en
Priority to IL16182302A priority patent/IL161823A0/en
Priority to MXPA04004467A priority patent/MXPA04004467A/en
Priority to YU39204A priority patent/RS52484B/en
Application filed by Pfizer Prod Inc, Abgenix Inc, Vahe Bedian, Ronald P Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng filed Critical Pfizer Prod Inc
Publication of WO2003040170A2 publication Critical patent/WO2003040170A2/en
Publication of WO2003040170A3 publication Critical patent/WO2003040170A3/en
Priority to TNP2004000078A priority patent/TNSN04078A1/en
Priority to IS7253A priority patent/IS2940B/en
Priority to IL161823A priority patent/IL161823A/en
Priority to ZA2004/04207A priority patent/ZA200404207B/en
Priority to HRP20040525AA priority patent/HRP20040525B1/en
Priority to NO20042388A priority patent/NO334339B1/en
Publication of WO2003040170A9 publication Critical patent/WO2003040170A9/en
Priority to HK05102440.7A priority patent/HK1069122A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.
PCT/US2002/036107 2001-11-09 2002-11-08 Antibodies to cd40 WO2003040170A2 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
NZ533180A NZ533180A (en) 2001-11-09 2002-11-08 A monoclonal antibody or antigen binding portion that specifically binds to and activates human CD40
APAP/P/2004/003034A AP1918A (en) 2001-11-09 2002-11-08 Antibodies to CD40
EA200400654A EA011449B1 (en) 2001-11-09 2002-11-08 Human monoclonal antibodies to cd40 and methods for use thereof
AU2002356926A AU2002356926B2 (en) 2001-11-09 2002-11-08 Antibodies to CD40
JP2003542215A JP4616555B2 (en) 2001-11-09 2002-11-08 Antibody against CD40
CA2466128A CA2466128C (en) 2001-11-09 2002-11-08 Antibodies to cd40
BRPI0214137A BRPI0214137B8 (en) 2001-11-09 2002-11-08 human monoclonal antibody or antigen-binding portion thereof that specifically binds to and activates human cd40, isolated hybridoma cell line, pharmaceutical composition comprising the same, use thereof in the manufacture of a drug and method of manufacturing said antibodies or antigen-binding portion of it
DK02802898.3T DK1476185T3 (en) 2001-11-09 2002-11-08 Antibodies to CD40
SI200231036T SI1476185T1 (en) 2001-11-09 2002-11-08 Antibodies to cd40
ES02802898T ES2432968T3 (en) 2001-11-09 2002-11-08 Antibodies against CD40
HU0402247A HU229829B1 (en) 2001-11-09 2002-11-08 Antibodies to cd40
CN028245709A CN1582165B (en) 2001-11-09 2002-11-08 Antibodies to CD40
IL16182302A IL161823A0 (en) 2001-11-09 2002-11-08 Antibodies to cd40 and pharmaceutical compositionscontaining the same
MEP-2008-814A ME00503B (en) 2001-11-09 2002-11-08 Antibodies to cd40
EP02802898.3A EP1476185B1 (en) 2001-11-09 2002-11-08 Antibodies to cd40
MXPA04004467A MXPA04004467A (en) 2001-11-09 2002-11-08 Antibodies to cd40.
YU39204A RS52484B (en) 2001-11-09 2002-11-08 Antibodies to cd40
TNP2004000078A TNSN04078A1 (en) 2001-11-09 2004-05-05 ANTIBODIES TO CD40
IL161823A IL161823A (en) 2001-11-09 2004-05-06 Antibodies to cd40 and pharmaceutical compositions containing the same
IS7253A IS2940B (en) 2001-11-09 2004-05-06 Antibodies against CD40
ZA2004/04207A ZA200404207B (en) 2001-11-09 2004-05-28 Antibodies to cd40
HRP20040525AA HRP20040525B1 (en) 2001-11-09 2004-06-08 Antibodies to cd40
NO20042388A NO334339B1 (en) 2001-11-09 2004-06-08 Antibody to CD40
HK05102440.7A HK1069122A1 (en) 2001-11-09 2005-03-22 Antibodies to cd40 cd40

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34898001P 2001-11-09 2001-11-09
US60/348,980 2001-11-09

Publications (3)

Publication Number Publication Date
WO2003040170A2 WO2003040170A2 (en) 2003-05-15
WO2003040170A3 true WO2003040170A3 (en) 2003-10-09
WO2003040170A9 WO2003040170A9 (en) 2004-06-10

Family

ID=23370387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036107 WO2003040170A2 (en) 2001-11-09 2002-11-08 Antibodies to cd40

Country Status (47)

Country Link
US (9) US7288251B2 (en)
EP (2) EP2343086A3 (en)
JP (3) JP4616555B2 (en)
KR (1) KR100830086B1 (en)
CN (2) CN103450360B (en)
AP (1) AP1918A (en)
AR (1) AR039067A1 (en)
AU (1) AU2002356926B2 (en)
BR (1) BRPI0214137B8 (en)
CA (1) CA2466128C (en)
CL (1) CL2009001779A1 (en)
CR (2) CR7343A (en)
CU (1) CU23745A3 (en)
CY (1) CY1115675T1 (en)
DK (1) DK1476185T3 (en)
DO (1) DOP2002000507A (en)
EA (1) EA011449B1 (en)
EC (1) ECSP045093A (en)
EG (1) EG25801A (en)
ES (1) ES2432968T3 (en)
GE (1) GEP20074222B (en)
GT (1) GT200200228A (en)
HK (1) HK1069122A1 (en)
HN (1) HN2002000318A (en)
HR (1) HRP20040525B1 (en)
HU (1) HU229829B1 (en)
IL (2) IL161823A0 (en)
IS (1) IS2940B (en)
MA (1) MA27139A1 (en)
ME (1) ME00503B (en)
MX (1) MXPA04004467A (en)
MY (1) MY137641A (en)
NI (1) NI200200128A (en)
NO (1) NO334339B1 (en)
NZ (1) NZ533180A (en)
OA (1) OA12725A (en)
PA (1) PA8557701A1 (en)
PE (1) PE20030846A1 (en)
PL (2) PL214634B1 (en)
PT (1) PT1476185E (en)
RS (1) RS52484B (en)
SI (1) SI1476185T1 (en)
TN (1) TNSN04078A1 (en)
TW (2) TWI331040B (en)
UY (1) UY27537A1 (en)
WO (1) WO2003040170A2 (en)
ZA (1) ZA200404207B (en)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244827B2 (en) * 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US20050255106A1 (en) * 1999-05-22 2005-11-17 Linda Diehl Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
WO2002020619A2 (en) 2000-09-07 2002-03-14 Schreiber John R HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
PT1391464E (en) 2001-04-27 2007-11-15 Kirin Pharma Kk Anti-cd40 monoclonal antibody
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
WO2003045318A2 (en) * 2001-11-21 2003-06-05 Celltech R & D, Inc. Manipulation of cytokine levels using cd83 gene products
ATE546150T1 (en) * 2002-06-07 2012-03-15 Zymogenetics Inc USE OF IL-21 AND MONOCLONAL ANTIBODIES TO TREAT SOLID TUMORS
US7052694B2 (en) * 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
EP1680140B1 (en) * 2003-10-16 2011-04-20 Imclone LLC Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
DK1694360T3 (en) * 2003-11-04 2010-10-18 Novartis Vaccines & Diagnostic Use of antagonist anti-CD40 antibodies to treat autoimmune and inflammatory diseases and organ transplant rejection
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CA2548015A1 (en) 2003-12-05 2005-06-23 John R. Schreiber Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
PL1707627T3 (en) 2003-12-25 2013-04-30 Kyowa Hakko Kirin Co Ltd Antagonistic anti-CD40 antibody mutant
KR20120048644A (en) 2004-01-09 2012-05-15 암젠 프레몬트 인코포레이티드 Antibodies to madcam
NZ550518A (en) 2004-03-23 2009-11-27 Biogen Idec Inc Agents that cross link TNF receptors for treating cancer
US20060099203A1 (en) * 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
JP5902367B2 (en) * 2004-06-30 2016-04-13 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ antibody
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
US20070286855A1 (en) * 2004-08-03 2007-12-13 Mayo Foundation For Medical Education And Research Improving treatments
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
DK1836225T3 (en) 2005-01-06 2012-02-27 Innate Pharma Sas Kir-binding agents and methods for using them
US8716451B2 (en) 2005-01-12 2014-05-06 Kyowa Hakko Kirin Co., Ltd Stabilized human IgG2 and IgG3 antibodies
CA2602375C (en) * 2005-03-23 2018-07-24 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
EP2444421A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
ES2429564T3 (en) * 2005-05-18 2013-11-15 Novartis Ag Procedures for the diagnosis and treatment of diseases that have an autoimmune and / or inflammatory component
US8337851B2 (en) * 2005-05-18 2012-12-25 Novartis Ag Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject for a CD40-expressing cancer
GB0512225D0 (en) * 2005-06-16 2005-07-27 Univ Sheffield Immunoglobulin molecules
AU2006269940C1 (en) 2005-07-18 2013-11-07 Seagen Inc. Beta-glucuronide-linker drug conjugates
TWI541253B (en) 2005-09-07 2016-07-11 艾默根佛蒙特有限公司 Human monoclonal antibodies to activin receptor-like kinase-1
WO2007103048A2 (en) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
AU2007248628B2 (en) 2006-05-03 2013-02-07 The Regents Of The University Of Colorado, A Body Corporate CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
JP4383525B2 (en) 2006-05-09 2009-12-16 ファイザー・プロダクツ・インク Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
EP1854810A1 (en) * 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
WO2007131575A1 (en) 2006-05-12 2007-11-22 Fondazione Centro San Raffaele Del Monte Tabor Tolerogenic dendritic cells, method for their production and uses thereof
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
WO2008072723A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. ANTI-Claudin-3 MONOCLONAL ANTIBODY, AND TREATMENT AND DIAGNOSIS OF CANCER USING THE SAME
PT2059534E (en) 2007-02-23 2012-07-17 Schering Corp Engineered anti-il-23p19 antibodies
JP2010518858A (en) 2007-02-23 2010-06-03 シェーリング コーポレイション Engineered anti-IL-23P19 antibody
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8039597B2 (en) * 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
AU2008323701B2 (en) 2007-11-07 2015-03-26 Genentech, Inc Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
EP2594590B1 (en) 2007-12-14 2014-11-12 Bristol-Myers Squibb Company Method of producing binding molecules for the human OX40 receptor
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
ATE542813T1 (en) 2008-08-06 2012-02-15 Pfizer 6-SUBSTITUTED 2-HETEROCYCLYLAMINOPYRAZINE COMPOUNDS AS CHK-1 INHIBITORS
JP2012501323A (en) * 2008-08-29 2012-01-19 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク Delivery of a CD40 agonist to a subject's tumor draining lymph nodes
EP2198878A1 (en) 2008-12-18 2010-06-23 University Of Miami Polypeptide bombesin antagonists
JO3382B1 (en) 2008-12-23 2019-03-13 Amgen Inc Human cgrp receptor binding antibodies
AU2016244220B2 (en) * 2008-12-23 2018-05-17 Amgen Inc. Human CGRP receptor binding proteins
AU2010229192A1 (en) * 2009-03-06 2011-09-29 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 24P4C12 proteins
JP5883653B2 (en) 2009-03-10 2016-03-15 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Antigen-presenting cell targeting antiviral vaccine
CN108373509A (en) * 2009-03-10 2018-08-07 贝勒研究院 The antiviral vaccine of target antigen presenting cells
CN102448989B (en) * 2009-03-10 2015-09-30 贝勒研究院 Anti-CD 40 antibodies and uses thereof
MX2011010938A (en) 2009-04-18 2012-01-12 Genentech Inc Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies.
WO2010123012A1 (en) * 2009-04-20 2010-10-28 協和発酵キリン株式会社 Antibody containing igg2 having amino acid mutation introduced therein
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
WO2011083391A2 (en) 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
ES2807217T3 (en) 2010-03-31 2021-02-22 Boehringer Ingelheim Int Anti-CD40 antibodies
GB201006096D0 (en) * 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
FR2959994B1 (en) 2010-05-12 2012-08-24 Lfb Biotechnologies NOVEL 12G4 MUTUS HUMANIZED ANTIBODIES AND THEIR FRAGMENTS DIRECTED AGAINST THE HUMAN TYPE II ANTI-MULLERIAN HORMONE RECEPTOR
EP3441404A1 (en) 2010-09-09 2019-02-13 Pfizer Inc 4-1bb binding molecules
AU2011310887A1 (en) * 2010-09-29 2013-05-02 Universite De Liege Combination of an agonistic anti-CD40 monoclonal antibody or a CD40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
AR083847A1 (en) 2010-11-15 2013-03-27 Novartis Ag FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
JP2014500879A (en) * 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Factors and methods for treating diseases correlated with BCMA expression
CN103347898B (en) * 2011-01-10 2017-12-05 Ct大西洋有限公司 Including the therapeutic alliance with tumor associated antigen binding antibody
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
PT2683406T (en) 2011-03-11 2019-07-08 Beth Israel Deaconess Medical Ct Inc Anti-cd40 antibodies and uses thereof
CA2830972C (en) 2011-04-19 2018-11-20 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
JP6152090B2 (en) * 2011-04-21 2017-06-21 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ Compositions and methods for treating optic neuritis
TWI598363B (en) 2011-04-21 2017-09-11 必治妥美雅史谷比公司 Antibody polypeptides that antagonize cd40
CN106928362B (en) 2011-04-29 2021-10-26 埃派斯进有限公司 anti-CD 40 antibodies and methods of use thereof
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
AP2014007588A0 (en) 2011-09-22 2014-04-30 Amgen Inc CD27L antigen binding proteins
CN104203982B (en) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 Polypeptide construct and application thereof
WO2013091661A2 (en) * 2011-12-23 2013-06-27 Aarhus Universitet Proteolytic resistant protein affinity tag
RS62454B1 (en) * 2012-01-31 2021-11-30 Regeneron Pharma Anti-asic1 antibodies and uses thereof
JP5798199B2 (en) * 2012-03-08 2015-10-21 国立研究開発法人科学技術振興機構 Anti-cancer agent
AR090263A1 (en) * 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
RU2737765C2 (en) 2012-05-04 2020-12-02 Пфайзер Инк. Prostate-associated antigens and immunotherapeutic regimens based on vaccines
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
ES2873877T3 (en) 2012-06-18 2021-11-04 Ospedale San Raffaele Srl Compositions and methods to decrease an immune response
CN109265552A (en) * 2012-10-30 2019-01-25 埃派斯进有限公司 Anti-CD 40 antibodies and its application method
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
CA2899960C (en) * 2013-02-01 2022-05-03 Transbio Ltd Anti-cd83 antibodies and use thereof
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
JP2016515544A (en) 2013-03-18 2016-05-30 バイオセルオーエックス プロダクツ ビー．ブイ． Humanized anti-CD134 (OX40) antibody and use thereof
MX370377B (en) 2013-04-29 2019-12-11 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b.
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
WO2014202552A1 (en) 2013-06-17 2014-12-24 Koninklijke Philips N.V. Magnetic resonance imaging subject support
GB201311487D0 (en) * 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
SI3444271T1 (en) 2013-08-08 2022-03-31 Cytune Pharma Il-15 and il-15ralpha sushi domain based modulokines
CA2923145A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
AR097584A1 (en) 2013-09-12 2016-03-23 Hoffmann La Roche ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
SG10201804030WA (en) 2013-10-25 2018-07-30 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
SG11201604594SA (en) * 2013-12-20 2016-07-28 Hoffmann La Roche Combination therapy with an anti-ang2 antibody and a cd40 agonist
US10286058B2 (en) 2014-01-13 2019-05-14 Baylor Research Institute Vaccines against HPV and HPV-related diseases
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
CA2943834A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
BR112016024546A2 (en) * 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft antibody or antibody fragment, antibody or isolated antibody fragment, antibody-drug conjugate, nucleic acid molecule, host cell, and pharmaceutical composition
UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
KR102443258B1 (en) 2014-08-12 2022-09-14 엘리게이터 바이오사이언스 에이비 Combination therapies with anti cd40 antibodies
BR112016029334A2 (en) * 2014-08-14 2018-01-09 Hoffmann La Roche pharmaceutical product, use of an antibody, kit, method for treating a cancer patient and methods and uses of new products
EP3070102A1 (en) 2015-03-18 2016-09-21 F. Hoffmann-La Roche AG Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies
US10934362B2 (en) 2014-09-15 2021-03-02 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
NZ731491A (en) 2014-10-23 2021-12-24 Kira Biotech Pty Ltd Cd83 binding proteins and uses thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EA036498B1 (en) 2014-10-29 2020-11-17 Сиэтл Дженетикс, Инк. Dosage and administration of non-fucosylated anti-cd40 antibodies
MX2017005481A (en) 2014-10-29 2017-10-26 Teva Pharmaceuticals Australia Pty Ltd Interferon a2b variants.
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
PT3283527T (en) 2015-04-13 2021-03-03 Five Prime Therapeutics Inc Combination therapy for cancer
JOP20200116A1 (en) 2015-04-24 2017-06-16 Amgen Inc Methods for treating or preventing migraine headache
BR122018004815A2 (en) 2015-04-30 2019-09-10 Psioxus Therapeutics Ltd oncolytic adenovirus encoding protein b7
CA2985718A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
CN107771184B (en) * 2015-06-29 2022-11-01 百时美施贵宝公司 Antibodies against CD40
KR20180021833A (en) * 2015-06-29 2018-03-05 더 락커펠러 유니버시티 Antibodies to CD40 with enhanced agonist activity
CN111375066B (en) 2015-07-16 2023-04-25 百欧肯治疗有限公司 Compositions and methods for treating cancer
EP3307322B1 (en) 2015-09-04 2021-02-17 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
ES2906823T3 (en) 2015-09-30 2022-04-20 Janssen Biotech Inc Agonist antibodies that specifically bind to human CD40 and methods of use
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
MA43023A (en) 2015-10-02 2018-08-08 Hoffmann La Roche HUMAN TRANSFERRIN / ANTI-HUMAN BISPECIFIC CD20 / ANTI-HUMAN RECEPTOR ANTIBODIES AND METHODS FOR USE THEREOF
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
KR20180072821A (en) 2015-11-03 2018-06-29 얀센 바이오테크 인코포레이티드 Antibodies that specifically bind to PD-1 and uses thereof
EP3757119A1 (en) * 2015-11-16 2020-12-30 Ubiprotein, Corp. A method for extending half-life of a protein
EP3386536A4 (en) * 2015-12-07 2019-07-31 Opi Vi- IP Holdco LLC Composition of antibody construct-agonist conjugates and methods of use thereof
JP7064437B2 (en) 2015-12-17 2022-05-10 サイオクサス セラピューティクス リミテッド Group B adenovirus encoding an anti-TCR complex antibody or fragment
MX2018010672A (en) 2016-03-04 2019-05-27 Univ Rockefeller Antibodies to cd40 with enhanced agonist activity.
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
CN109069638B (en) 2016-03-24 2022-03-29 璟尚生物制药公司 Trispecific inhibitors for cancer therapy
MA43835A (en) 2016-03-25 2018-11-28 Seattle Genetics Inc PROCESS FOR THE PREPARATION OF PEGYLATED MEDICINAL PRODUCTS AND THEIR INTERMEDIARIES
US20170342169A1 (en) 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Bispecific binding proteins
IL263223B2 (en) 2016-05-27 2023-03-01 Abbvie Biotherapeutics Inc Anti-cd40 antibodies and their uses
CA3026880A1 (en) 2016-06-08 2017-12-14 Paul Foster Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
EP3470424A4 (en) 2016-06-08 2020-03-04 Shanghai Jiaotong University School of Medicine Sequence of antibody heavy chain constant region for enhancing agonist antibody activity
BR112018076260A2 (en) 2016-06-20 2019-03-26 Kymab Limited antibody or fragment thereof that specifically binds to hpd-11, bispecific antibody or fusion protein, use of an antibody or fragment, method, pharmaceutical composition, modulation method, inhibition method, treatment method, nucleic acid, vector, host and immunocytocin
BR112019000512A2 (en) 2016-07-14 2019-04-24 Genmab A/S antibody, nucleic acid, expression vector, host cell, composition, methods of treating a disease, to produce a bispecific antibody and to detect if cross-linking between cd40 and cd137 expressing cells occurs in a sample, use of a multispecific antibody and kit
JP7241677B2 (en) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Anti-CD47 combination therapy
CN109843916B (en) 2016-08-12 2023-10-31 詹森生物科技公司 Fc-engineered anti-TNFR superfamily member antibodies with enhanced agonistic activity and methods of use thereof
CA3033661A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
WO2018036852A1 (en) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
US11905331B2 (en) 2016-11-11 2024-02-20 Kumho Ht, Inc. Antibody binding specifically to CD40 and use thereof
KR20190095941A (en) 2016-12-19 2019-08-16 그렌마크 파머수티칼스 에스. 아. New TNFR Agonists and Their Uses
CN110072553B (en) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 Treatment of tumors with anti-CSF-1R antibodies in combination with anti-PD-L1 antibodies after failure of anti-PD-L1/PD 1 treatment
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
CA3049842A1 (en) * 2017-02-02 2018-08-09 Silverback Therapeutics, Inc. Construct-peptide compositions and methods of use thereof
KR20190115057A (en) 2017-02-10 2019-10-10 젠맵 비. 브이 Polypeptide Variants and Uses thereof
CA3056011A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
JP2020512312A (en) 2017-03-24 2020-04-23 シアトル ジェネティックス， インコーポレイテッド Process for the preparation of glucuronide drug-linker and its intermediates
CA3055433A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Humanized anti-cd40 antibodies
EP3604384B1 (en) 2017-03-30 2021-09-08 NOF Corporation Hydrophilic polymer derivative having self-immolative acetal linker and composite using same
EP3604385A4 (en) 2017-03-30 2021-01-20 NOF Corporation Heterobifunctional monodispersed polyethylene glycol, and complex using same
TWI704158B (en) * 2017-04-04 2020-09-11 瑞士商赫孚孟拉羅股份公司 Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
CN110505883A (en) 2017-04-13 2019-11-26 豪夫迈·罗氏有限公司 Proleulzin immunoconjugates used in method for treating cancer, CD40 agonist, and optionally PD-1 axis binding antagonists
WO2018220207A1 (en) 2017-06-01 2018-12-06 Psioxus Therapeutics Limited Oncolytic virus and method
JP7257971B6 (en) 2017-06-01 2023-07-24 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Anti-CD40 Antibodies, Antigen-Binding Fragments Thereof, and Medical Uses Thereof
TW201902462A (en) 2017-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 Novel administration routes for immune agonists
EP3418302A1 (en) 2017-06-19 2018-12-26 F. Hoffmann-La Roche AG Administration routes for immune agonists
CU20200002A7 (en) 2017-07-14 2020-11-30 Pfizer ANTIBODIES AGAINST MADCAM
CN111511762A (en) 2017-08-21 2020-08-07 天演药业公司 anti-CD137 molecules and uses thereof
SG11202002366VA (en) 2017-09-19 2020-04-29 Mab Discovery Gmbh Agonistic cd40 antibodies
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
EP3708589A4 (en) 2017-11-08 2021-08-11 Kyowa Kirin Co., Ltd. BISPECIFIC ANTIBODY WHICH BINDS TO CD40 AND EpCAM
CN111788227A (en) 2017-12-27 2020-10-16 百时美施贵宝公司 anti-CD 40 antibodies and uses thereof
CN109971723B (en) * 2017-12-28 2023-07-07 上海细胞治疗研究院 T cells comprising CD40 antibody and muc1 specific chimeric antigen receptor gene and uses thereof
CN109971717B (en) * 2017-12-28 2023-06-20 上海细胞治疗研究院 T cells co-expressing CD40 antibody and mesothelin specific chimeric antigen receptor and uses thereof
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
JP7204078B2 (en) 2018-03-13 2023-01-16 日油株式会社 Heterobifunctional compounds with monodispersed polyethylene glycols in main and side chains
CN111954719A (en) 2018-03-26 2020-11-17 美国安进公司 Total defucosylated glycoforms of antibodies produced in cell culture
SG11202009629YA (en) 2018-04-02 2020-10-29 Amgen Inc Erenumab compositions and uses thereof
JP2021521804A (en) * 2018-04-20 2021-08-30 リビジェン バイオファーマ カンパニー リミテッド Anti-CD40 antibody and its use
US20200017596A1 (en) * 2018-05-10 2020-01-16 Abvision, Inc. Monoclonal antibodies activating cd40 and uses thereof
US20190365719A1 (en) * 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Combination treatments of hsp90 inhibitors for enhancing tumor immunogenicity and methods of use thereof
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US10597453B2 (en) 2018-06-29 2020-03-24 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
TWI803682B (en) 2018-08-20 2023-06-01 美商輝瑞股份有限公司 Anti-gdf15 antibodies, compositions and methods of use
US20210355216A1 (en) 2018-10-05 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and systems for controlling the agonistic properties of antibody variable domains by light
KR20210097750A (en) 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 CD40 antibody pharmaceutical compositions and uses thereof
US20220025060A1 (en) 2018-11-30 2022-01-27 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd40 antibody, antigen binding fragmentand pharmaceutical use thereof
US20220089758A1 (en) * 2019-01-22 2022-03-24 Revmab Biosciences Usa, Inc. Novel anti-cd40 antibodies
US10570210B1 (en) 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
KR20220004985A (en) 2019-03-27 2022-01-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Recombinant protein with CD40 activation properties
AU2020256828A1 (en) 2019-04-10 2021-11-18 Nankai University Anti-CD40 antibody and use thereof
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
AU2020276931A1 (en) 2019-05-15 2021-12-16 Kyowa Kirin Co., Ltd. Bispecific antibody binding to CD40 and FAP
EP3971293A4 (en) 2019-05-15 2023-02-08 Kyowa Kirin Co., Ltd. Bispecific antibody capable of binding to cd40 and gpc3
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
EP4027998A1 (en) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
WO2021062372A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
CA3156027A1 (en) 2019-09-26 2021-04-01 Nof Corporation Heterobifunctional monodispersed polyethylene glycol having peptide linker
CA3163358A1 (en) * 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
AR120832A1 (en) 2019-12-20 2022-03-23 Amgen Inc MULTISPECIFIC ANTIBODY CONSTRUCTS CD40 AGONISTS TARGETING MESOTHELIN FOR THE TREATMENT OF SOLID TUMORS
US20210214454A1 (en) * 2020-01-10 2021-07-15 Symphogen A/S Anti-cd40 antibodies and compositions
IL272194A (en) 2020-01-22 2021-07-29 Yeda Res & Dev Multispecific antibodies for use in treating diseases
CN115702002A (en) 2020-04-23 2023-02-14 朝途生物疗法株式会社 Improved peptide vaccines
CA3178478A1 (en) 2020-05-14 2021-11-18 Valerie Perrine Calabro Recombinant cd40 binding proteins and their use
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
BR112022024063A2 (en) 2020-05-26 2023-01-31 Inst Nat Sante Rech Med CORONAVIRUS 2 POLYPEPTIDES OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS-COV-2) AND USES THEREOF FOR VACCINE PURPOSES
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
MX2023004364A (en) 2020-10-15 2023-05-03 Amgen Inc Relative unpaired glycans in antibody production methods.
WO2022101302A1 (en) 2020-11-12 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
KR20230124672A (en) 2020-12-23 2023-08-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Chlamydia vaccine based on targeting of MOMP VS4 antigen to antigen presenting cells
TW202241479A (en) 2020-12-30 2022-11-01 美商安迅生物製藥公司 Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
CA3204291A1 (en) 2021-01-13 2022-07-21 F. Hoffmann-La Roche Ag Combination therapy
CA3209251A1 (en) 2021-01-29 2022-08-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
EP4284919A1 (en) 2021-01-29 2023-12-06 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
EP4305066A1 (en) 2021-03-09 2024-01-17 Genmab A/S Multispecific binding agents against cd40 and cd137 in therapy
JP2024512669A (en) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Tanotransmission polypeptides and their use in the treatment of cancer
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
KR20240026185A (en) * 2021-06-28 2024-02-27 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Anti-CD40 antibodies, antigen-binding fragments and medical uses thereof
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
US20230203176A1 (en) * 2021-09-17 2023-06-29 Novartis Ag Methods For Prevention Of Graft Rejection In Xenotransplantation
AU2022358474A1 (en) * 2021-10-01 2024-03-28 Mab Discovery Gmbh Agonistic cd40 antibodies as immune stimulatory agents
CA3233279A1 (en) 2021-10-05 2023-04-13 Amagen, Inc. Fc-gamma receptor ii binding and glycan content
WO2023088968A1 (en) 2021-11-17 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Universal sarbecovirus vaccines
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023172890A2 (en) * 2022-03-07 2023-09-14 Agenus Inc. Anti-ilt2 antibodies and uses thereof
WO2023193239A1 (en) 2022-04-08 2023-10-12 Peter Peizhi Luo Anti-cd28 antibodies and methods of use thereof
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
CN115969997B (en) * 2022-12-19 2024-02-13 华润生物医药有限公司 Antibody drug conjugate targeting CLDN18.2 and application thereof
CN116375870B (en) * 2022-12-30 2023-09-15 优睿赛思(武汉)生物科技有限公司 Humanized antibody of anti-human CD40 protein, preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312693B1 (en) * 1998-02-19 2001-11-06 Alejandro A. Aruffo Antibodies against human CD40

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US59427A (en) * 1866-11-06 Improvement in fences
US142358A (en) * 1873-09-02 Improvement in the purification of illuminating-gas
US439216A (en) * 1890-10-28 Maker
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
JP2532858B2 (en) 1985-04-01 1996-09-11 セルテツク リミテツド Transformed myeloma cell line
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (en) 1990-07-10 1999-10-15 Cambridge Antibody Tech METHOD FOR PRODUCING SPECIFIC BONDING PAIRS
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (en) 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech Inc METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
US5416367A (en) * 1991-03-06 1995-05-16 Quicklogic Corporation Programmable application specific integrated circuit and logic cell therefor
IE921169A1 (en) 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ATE181571T1 (en) 1991-09-23 1999-07-15 Medical Res Council METHODS FOR PRODUCING HUMANIZED ANTIBODIES
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
JPH05242071A (en) * 1991-11-20 1993-09-21 Mitsubishi Electric Corp Control or decision/estimation of object system and its device
CA2129663C (en) 1992-02-06 2005-07-05 James S. Huston Biosynthetic binding protein for cancer marker
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
PT804070E (en) 1993-03-09 2000-11-30 Genzyme Corp ISOLATION OF COMPONENTS OF INTEREST FROM MILK.
CA2172376C (en) 1993-10-01 2008-11-18 William C. Fanslow, Iii Antibodies to cd40
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
NZ278740A (en) * 1993-12-23 1998-05-27 Immunex Corp Treating disease characterised by neoplastic cells expressing cd40 using a cd40 binding protein
US5612126A (en) * 1994-01-19 1997-03-18 Burlington Industries, Inc. Stiff fabric and method of forming the stiff fabric
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
JPH0812700A (en) 1994-07-01 1996-01-16 Sumitomo Electric Ind Ltd Monoclonal antibody against mouse cd40
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
GB9425060D0 (en) * 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
WO1996032181A1 (en) * 1995-04-11 1996-10-17 Robert Bosch Gmbh Process and device for reducing pollutants, especially nitrogen oxides in combustion exhaust gases
MX9708026A (en) 1995-04-20 1997-11-29 Pfizer Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors.
CA2218489A1 (en) 1995-04-21 1996-10-24 Aya Jakobovits Generation of large genomic dna deletions
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5780215A (en) * 1995-07-26 1998-07-14 Konica Corporation Silver halide color photographic light-sensitive material
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE225343T1 (en) 1995-12-20 2002-10-15 Hoffmann La Roche MATRIX METALLOPROTEASE INHIBITORS
KR100489174B1 (en) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-anilinoquinazoline derivatives
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
ID19609A (en) 1996-07-13 1998-07-23 Glaxo Group Ltd HETEROSICLIC COMPOUNDS
BR9710362A (en) 1996-07-13 1999-08-17 Glaxo Group Ltd Pharmaceutical formulation compound uses a compound processes of treatment of a human or animal suffering from a mediated by abnormal activity of protein tyrosine kinase and for the preparation of a compound
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
WO1998003516A1 (en) 1996-07-18 1998-01-29 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
CN1228083A (en) 1996-08-23 1999-09-08 美国辉瑞有限公司 Arylsulfonylamino hydroxamic acid derivatives
US5817690A (en) * 1996-08-27 1998-10-06 American Home Products Corporation 4-aminoethoxy indolone derivatives
ID18494A (en) 1996-10-02 1998-04-16 Novartis Ag PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
DK0950059T3 (en) 1997-01-06 2004-11-01 Pfizer Cyclic sulfone derivatives
CA2279276C (en) 1997-02-03 2005-09-13 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
BR9807824A (en) 1997-02-07 2000-03-08 Pfizer Derivatives of n-hydroxy-beta-sulfonyl-propionamide and its use as matrix metalloproteinase inhibitors
CA2280151C (en) 1997-02-11 2005-12-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
JP2002512624A (en) 1997-05-21 2002-04-23 バイオベーション リミテッド Method for producing non-immunogenic protein
EP0984692A4 (en) 1997-05-30 2001-02-21 Merck & Co Inc Novel angiogenesis inhibitors
DE69838172T2 (en) 1997-08-22 2008-04-10 Astrazeneca Ab OXINDOLYLCHINAZOLE DERIVATIVES AS ANGIOGENESEHEMMER
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
CN1280580A (en) 1997-11-11 2001-01-17 辉瑞产品公司 Thienopyrimidine and thienopyridine derivatives useful as anti-cancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
AU2978899A (en) 1998-03-03 1999-09-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
JP4462654B2 (en) 1998-03-26 2010-05-12 ソニー株式会社 Video material selection device and video material selection method
PA8469501A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
PA8469401A1 (en) 1998-04-10 2000-05-24 Pfizer Prod Inc BICYCLE DERIVATIVES OF HYDROXAMIC ACID
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
AU4009899A (en) * 1998-05-23 1999-12-13 Tanox, Inc. Molecules targeting cd40 and tumor cells
SK287132B6 (en) 1998-05-29 2009-12-07 Sugen, Inc. Pharmaceutical composition containing pyrrole substituted 2-indolinone, kit containing mentioned composition and use pyrrole substituted 2-indolinone
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
US6114361A (en) 1998-11-05 2000-09-05 Pfizer Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
PT2112166T (en) 1998-12-23 2019-01-30 Pfizer Human monoclonal antibodies to ctla-4
WO2000066155A1 (en) * 1999-04-30 2000-11-09 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
US20030118588A1 (en) * 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6482411B1 (en) * 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
AU3662101A (en) * 2000-02-01 2001-08-14 Tanox Inc Cd40-binding apc-activating molecules
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
AU2001259215A1 (en) * 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
MY143465A (en) 2001-01-05 2011-05-13 Pfizer Antibodies to insulin-like growth factor i receptor
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
KR20120048644A (en) 2004-01-09 2012-05-15 암젠 프레몬트 인코포레이티드 Antibodies to madcam
US10181126B2 (en) 2012-03-13 2019-01-15 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312693B1 (en) * 1998-02-19 2001-11-06 Alejandro A. Aruffo Antibodies against human CD40

Also Published As

Publication number Publication date
ECSP045093A (en) 2004-07-23
OA12725A (en) 2006-06-28
JP4616555B2 (en) 2011-01-19
US8388971B2 (en) 2013-03-05
CL2009001779A1 (en) 2010-02-05
KR100830086B1 (en) 2008-05-20
NO20042388L (en) 2004-08-09
HUP0402247A2 (en) 2005-01-28
US20090130715A1 (en) 2009-05-21
RS52484B (en) 2013-02-28
AU2002356926B2 (en) 2007-01-04
PL214289B1 (en) 2013-07-31
MY137641A (en) 2009-02-27
KR20050063749A (en) 2005-06-28
HRP20040525A2 (en) 2005-04-30
BR0214137A (en) 2004-09-14
IS2940B (en) 2016-03-15
ZA200404207B (en) 2005-08-31
US20160152713A1 (en) 2016-06-02
US20100098694A1 (en) 2010-04-22
AU2002356926A2 (en) 2003-05-19
BRPI0214137B1 (en) 2019-03-19
EG25801A (en) 2012-08-08
TWI331040B (en) 2010-10-01
TWI338579B (en) 2011-03-11
AU2002356926C1 (en) 2003-05-19
PL214634B1 (en) 2013-08-30
AR039067A1 (en) 2005-02-09
MXPA04004467A (en) 2005-05-16
US20120225014A1 (en) 2012-09-06
PT1476185E (en) 2013-11-05
AP1918A (en) 2008-11-13
NZ533180A (en) 2008-03-28
HRP20040525B1 (en) 2017-06-02
ME00503B (en) 2011-10-10
EP1476185B1 (en) 2013-07-31
IS7253A (en) 2004-05-06
CN1582165B (en) 2013-05-29
CN1582165A (en) 2005-02-16
GEP20074222B (en) 2007-10-25
ES2432968T3 (en) 2013-12-05
DOP2002000507A (en) 2003-05-15
EA200400654A1 (en) 2004-12-30
CY1115675T1 (en) 2017-01-25
PA8557701A1 (en) 2003-12-19
UY27537A1 (en) 2003-02-28
AP2004003034A0 (en) 2004-06-30
NI200200128A (en) 2010-01-11
TW201034686A (en) 2010-10-01
GT200200228A (en) 2008-09-26
IL161823A (en) 2014-02-27
US7288251B2 (en) 2007-10-30
SI1476185T1 (en) 2013-12-31
EA011449B1 (en) 2009-02-27
IL161823A0 (en) 2005-11-20
PL392809A1 (en) 2011-03-14
NO334339B1 (en) 2014-02-10
CU23745A3 (en) 2012-01-31
HUP0402247A3 (en) 2012-09-28
TW200306204A (en) 2003-11-16
US20030211100A1 (en) 2003-11-13
US20130024956A1 (en) 2013-01-24
US20090169563A1 (en) 2009-07-02
US20060093600A1 (en) 2006-05-04
JP2013099333A (en) 2013-05-23
EP1476185A2 (en) 2004-11-17
PL370514A1 (en) 2005-05-30
CN103450360B (en) 2016-11-02
JP2005508176A (en) 2005-03-31
WO2003040170A9 (en) 2004-06-10
PE20030846A1 (en) 2003-10-11
HK1069122A1 (en) 2005-05-13
US20070190051A1 (en) 2007-08-16
CR10878A (en) 2011-01-12
US7563442B2 (en) 2009-07-21
CN103450360A (en) 2013-12-18
RS39204A (en) 2006-12-15
TNSN04078A1 (en) 2006-06-01
MA27139A1 (en) 2005-01-03
JP2010213704A (en) 2010-09-30
DK1476185T3 (en) 2013-10-14
US7338660B2 (en) 2008-03-04
HN2002000318A (en) 2003-03-10
WO2003040170A2 (en) 2003-05-15
BRPI0214137B8 (en) 2021-05-25
US7618633B2 (en) 2009-11-17
US7626012B2 (en) 2009-12-01
JP5547532B2 (en) 2014-07-16
EP2343086A2 (en) 2011-07-13
JP5848232B2 (en) 2016-01-27
CA2466128C (en) 2013-10-29
CR7343A (en) 2004-10-28
HU229829B1 (en) 2014-09-29
EP2343086A3 (en) 2012-02-22
EP1476185A4 (en) 2007-04-04
CA2466128A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
WO2003040170A3 (en) Antibodies to cd40
WO2005067620A8 (en) ANTIBODIES TO MAdCAM
WO2005030124A3 (en) Antibodies to m-csf
WO2002053596A3 (en) Antibodies to insulin-like growth factor i receptor
WO2003085089A3 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
WO2006116269A3 (en) Antibodies to myostatin
WO2008019290A3 (en) Human antibodies to erbb 2

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-392/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 566/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2466128

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 161823

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1200400414

Country of ref document: VN

Ref document number: 1020047006992

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/004467

Country of ref document: MX

Ref document number: 2003542215

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: AP/P/2004/003034

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 2002356926

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004/04207

Country of ref document: ZA

Ref document number: 533180

Country of ref document: NZ

Ref document number: 200404207

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: DZP2004000146

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: P20040525A

Country of ref document: HR

Ref document number: 04053734

Country of ref document: CO

Ref document number: 200400654

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 5640

Country of ref document: GE

Ref document number: 8256

Country of ref document: GE

Ref document number: 2002802898

Country of ref document: EP

Ref document number: 20028245709

Country of ref document: CN

COP Corrected version of pamphlet

Free format text: PAGES 1/19-19/19, DRAWINGS, REPLACED BY CORRECT PAGES 1/18-18/18; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500651

Country of ref document: PH

WWP Wipo information: published in national office

Ref document number: 2002802898

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002356926

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: CR2009-010878

Country of ref document: CR